How to read: Every bubble is one Indian imipenem exporter. X-axis = shipment count; Y-axis = average unit price; bubble size = total revenue. Dashed lines split at the median — exporters in the top-right (Bulk Leaders) combine high volume with premium pricing.
HOW TO READ THIS REPORT
60 seconds
Scan this page — KPIs, thesis, flagship chart, top findings
5 minutes
Read every Key Takeaway line across §1–§9
30 minutes
Read sections tagged for your role ([S] or [B]) end-to-end
In depth
Drill into §10 for your country · supplier / buyer directories at end
02
PART I — OVERVIEW
About This Report
Data sources, methodology, trust signals, and what this Imipenem report covers
KEY TAKEAWAYEvery figure in this report is grounded in real commercial imipenem trade records. Data comes from official customs filings and public trade sources, runs through a multi-layer quality process, and lands in a clean, consistent report you can rely on.
S FOR SUPPLIERS
Every competitor benchmark, market share figure, and buyer list in this report comes from verified commercial shipments — not surveys or estimates. Use them with confidence when planning your next pitch.
B FOR BUYERS
Every supplier profile, price benchmark, and trade route in this report reflects what that supplier actually ships — real volumes, real destinations, real prices. Use them to qualify and compare Indian imipenem suppliers.
§2.1 Reporting parameters · the scope of this 2025-Q4 Imipenem India trade report
P
Product scope
Imipenem
All variants merged — branded and generic formulations of imipenem
T
Time period
2025-Q4
October, November, December 2025 — a single-quarter snapshot
S
Data sources
Official & public trade records
Government customs filings, public trade databases and licensed commercial feeds
G
Geography
India origin → global
Indian sea and air ports shipping to destination markets worldwide
C
Currency
USD (FOB)
Declared Free-on-Board value at the Indian port of loading
R
Shipments analysed
45
Every commercial imipenem trade record in the period, aggregated and deduplicated
§2.2 Our quality process · Figure 2.1
Figure 2.1 From raw trade records to a clean report — the four quality pillars.
How to read: Raw trade data (left) flows through four quality checks — source verification, format standardisation, entity matching, and deduplication — to produce the clean, reliable data (right) behind every chart and table in this report.
§2.3 Trust signals · what you can rely on in the numbers you read
DATA COVERAGE
10M+
Pharmaceutical trade records across the full TransData Nexus platform.
COUNTRIES
150+
Origin and destination countries covered in the global pharma trade database.
Platform refresh cadence. This report is a snapshot from the same live data.
§2.4 Limitations · what the data does and does not tell you
WHAT THIS DATA DOES AND DOES NOT SAY
Prices are at the Indian port of loading (FOB), not the final delivered cost in the destination country. Freight, insurance, import duty and local margin are not included.
This is a single-quarter snapshot. Multi-quarter trends, year-over-year growth and historical comparisons are available on the full platform.
A small number of records have incomplete transport mode or destination port fields; these appear blank in the shipment register but are still counted in totals.
This report is a commercial intelligence tool, not a legal audit. For high-stakes decisions, cross-reference with the underlying trade records via the full platform.
03
PART II — MARKET STRUCTURE
Quarterly Trade Overview
Monthly trends, regional performance, and ranking shifts — 2025-Q4
KEY TAKEAWAY2025-Q4 followed a mixed: Oct $439.6K, Nov $522.3K, Dec $513.7K. Shipment counts rose across the quarter.
S FOR SUPPLIERS
Track which months your competitors were most active, which destinations rose or fell, and whether the Nov dip hit your segment. The bump charts show rank movement — watch for rivals climbing past you.
B FOR BUYERS
Identify whether your current Indian supplier maintained steady shipments through the quarter, or whether they pulled back. Steady suppliers during dips signal reliable partnerships.
1
$439.6K
Oct USD
5 shipments
2
$522.3K
Nov USD
+18.8% MoM
3
$513.7K
Dec USD
-1.6% MoM
4
Mixed
Q4 growth shape
Oct → Nov → Dec
Fig 3.1 Nov rose 18.8% in USD but shipment count kept climbing.
How to read: Blue bars = monthly USD. Orange line = shipment count. When bars drop but line rises, average shipment value fell. Insight: Oct opened at $440K, making it the weakest month by value.
How to read: The curve shows the running total across the quarter. A steeper slope means that month contributed more revenue. Insight: The curve’s steepest section reveals which month drove the most trade value.
How to read: Each coloured layer is one destination region. Layer height = USD in that month. Insight: The top region contributed the most, while the smallest region had the least volume.
How to read: Each line traces a supplier’s monthly rank. Flat = stable position; crossing = rank change. Insight: SUN PHARMACEUTICAL INDUSTRIES LTD maintained its leading position.
04
PART II — MARKET STRUCTURE
Global Destination Map
Which countries import imipenem from India, how much they buy, and who supplies each market
KEY TAKEAWAYMexico absorbs 28.1% of India’s 2025-Q4 imipenem trade ($414.0K). Beyond the top 10 destinations, 26 countries have fewer than 5 Indian suppliers each — white-space markets where new entrants face minimal competition. Asia has 9 destination countries, the widest regional diversity.
S FOR SUPPLIERS
Use the flow map and lanes table to see which destinations your competitors dominate. For small and mid-size suppliers: look beyond the leading markets — the 26 countries in the long tail have fewer than 5 Indian suppliers each and low competitive barriers.
B FOR BUYERS
Find your country on the map to see how much imipenem India ships to your market, who the top suppliers are, and whether you’re in a concentrated or competitive corridor.
Asia
$253K
17.2% of trade
9 countries · 15 shipments
Europe
$629K
42.6% of trade
5 countries · 10 shipments
Americas
$505K
34.2% of trade
5 countries · 8 shipments
Africa
$88K
6.0% of trade
7 countries · 12 shipments
Fig 4.1 Mexico is the #1 corridor ($414K) — 26 flow arcs from India radiate across 4 continents.
How to read: The world map shows every country colored by how much Indian imipenem it receives (light = low, dark = high). Orange arcs radiate from India to the top 26 destinations; arc thickness = USD value. All destinations are labeled with country name + USD.
§4.1 Top 10 bilateral trade lanes (India → destination) with top Indian suppliers
#
Destination
Total USD
Ships
#1 Indian supplier
USD
#2 Indian supplier
USD
#3 Indian supplier
USD
1
Mexico
$414K
4
VENUS REMEDIES LTD
$414K
—
—
—
—
2
Belgium
$365K
5
SUN PHARMACEUTICAL INDUSTRIES LTD
$365K
—
—
—
—
3
Netherlands
$203K
2
SUN PHARMACEUTICAL INDUSTRIES LTD
$203K
—
—
—
—
4
Saudi Arabia
$150K
3
VENUS REMEDIES LTD
$150K
—
—
—
—
5
Bolivia
$65K
1
KWALITY PHARMACEUTICALS LTD
$65K
—
—
—
—
6
Nepal
$51K
3
ALKEM LABORATORIES LTD
$35K
M. J. BIOPHARM PVT LTD
$16K
—
—
7
Madagascar
$35K
1
G S PHARMA PVT LTD
$35K
—
—
—
—
8
Hong Kong
$28K
1
VENUS REMEDIES LTD
$28K
—
—
—
—
9
Albania
$28K
1
NOVO MEDI SCIENCES PVT LTD
$28K
—
—
—
—
10
Hungary
$24K
1
VENUS REMEDIES LTD
$24K
—
—
—
—
Table 4.1 — Top 10 destination countries ranked by trade value, with the largest Indian suppliers for each market.
Fig 4.2 Asia leads at 17.2% of USD — but Mexico is the single largest market.
How to read: Column width = region USD share. Within each column, cells are stacked by country, height = share within region.
§4.2 Destination concentration
28.1%
#1 country share
Mexico alone
81.2%
Top 5 share
5 of 26 countries
98.1%
Top 15 share
Long tail of 11 countries = 1.9%
HHI 1748
Destination HHI
Moderately concentrated
26
Countries served
Global pharma reach from India
9
Asia countries
Widest regional diversity
Source: TransData Nexus trade data platform
05
PART III — WHO’S IN THIS MARKET
Indian Supplier Rankings & Profiles
19 Indian exporters ranked by value — profiles, portfolios, and competitive intelligence
KEY TAKEAWAYVENUS REMEDIES LTD ($631.5K, 42.8% share) and SUN PHARMACEUTICAL INDUSTRIES LTD ($600.1K) together control 83.5% of India’s 2025-Q4 imipenem trade. The top 5 suppliers hold 92.6%. 19 companies shipped at least once.
S FOR SUPPLIERS
Find your rank, your competitors’ ranks, and the gap in USD/share between you. The profile pages show each top supplier’s buyer portfolio, dosage mix and route map — your competitive-intelligence toolkit.
B FOR BUYERS
Find potential Indian imipenem suppliers ranked by size, catalog breadth and destination reach. The profile pages reveal which suppliers have proven trade lanes to your region.
Fig 5.1 VENUS REMEDIES LTD leads by $31K over SUN PHARMACEUTICAL INDUSTRIES LTD — top 19 Indian exporters ranked by trade value
How to read: Each bar = one Indian supplier ranked by USD. The (#N) shows their rank by shipment count — mismatches reveal pricing strategy. Insight: MDS ENTERPRISES is #18 by value but #5 by volume.
Fig 5.2 VENUS REMEDIES LTD also leads by shipment count (14) but ranking shifts for volume-heavy players
How to read: Same suppliers re-ranked by shipment count. The (#N) shows their rank by USD value. Insight: MDS ENTERPRISES moves from #5 by volume to #18 by value — fewer but higher-value shipments.
05
PART III — WHO’S IN THIS MARKET
Supply Landscape — Archetypes & Concentration
How India’s 19 imipenem suppliers split into strategic segments
KEY TAKEAWAY5 suppliers (25%) generate 92.6% of total trade value. The market splits into four archetypes: Market Leaders, High-Value specialists, Volume players, and a long tail.
Fig 5.3 VENUS REMEDIES LTD and SUN PHARMACEUTICAL INDUSTRIES LTD sit in the leaders zone — high volume AND high value.
How to read: Each bubble is one Indian supplier. X-axis = shipment count (log scale); Y-axis = total USD value (log scale); bubble size = revenue. Blue dashed lines split at the median. Market Leaders (top-right) combine high volume with high value. Premium Niche (top-left) ship fewer but higher-value consignments. Volume Players (bottom-right) compete on quantity. Long-Tail (bottom-left) are small or occasional exporters. Conclusion: the log scale reveals clear strategic clusters — use this map to identify where your company sits relative to competitors.
Fig 5.4 25% of suppliers = 92.6% of USD — classic concentration.
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 5 destinations and up to 2 importers per destination.
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 5 destinations and up to 2 importers per destination.
06
PART III — WHO’S IN THIS MARKET
Global Buyer Rankings & Intelligence
26 importers across 26 countries — who is buying Indian imipenem and how much
KEY TAKEAWAYThe demand side is dramatically more fragmented than supply: the top 24 importers together hold only 85.8% of total USD. 92% of buyers source from a single Indian supplier — a vast pool of lock-in candidates.
S FOR SUPPLIERS
Find the importers buying from your competitors. The rankings reveal who has volume, who pays well, and who sources from multiple Indian suppliers (potential pitch targets).
B FOR BUYERS
See where you rank among global importers of Indian imipenem. Compare your USD and shipment count against peers in your country and dosage segment.
Fig 6.1 L J S A D E C V is the #1 importer at $359K (24.4%) — top 24 by trade value
How to read: Left semicircle = top 19 Indian suppliers; right = top 20 global buyers. Arc length = total USD; colored ribbons = individual relationships, thickness = USD value. Insight: follow the thickest ribbons to identify the dominant trading pairs.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
How Indian imipenem prices vary by supplier, country and dosage form
KEY TAKEAWAYImipenem prices span 21551× ($0.0010 → $21.02). The coefficient of variation is 1.49. Dosage form, not destination, is the primary price driver.
S FOR SUPPLIERS
Use the box plot to see where your product sits on the price spectrum. The tornado chart shows exactly where you sit relative to the market median.
B FOR BUYERS
Use this section to benchmark the price you pay against the market. The percentile strip tells you if your current supplier is charging you premium, mid-market or budget rates.
How to read: Each bar shows one supplier’s average unit price relative to the market median (dashed line). Red = above median (premium), green = below (budget).
COMMODITY KINGS
high volume · low unit price
Bulk API/tablet. Largest absolute USD despite lowest per-unit prices. e.g. VENUS REMEDIES LTDSourcing: best for cost-driven procurement.
BULK LEADERS
high volume · premium price
Branded-generic leaders, above-median pricing. e.g. SUN PHARMACEUTICAL INDUSTRIESSourcing: hardest to displace; compete on relationship.
LONG-TAIL
low volume · low unit price
Spot/opportunistic players. Sourcing: first to approach for new tenders.
PREMIUM NICHE
low volume · premium price
Sterile injectables and infusions. Hospital-grade. Sourcing: expect 10× price vs tablet.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
Outlier forensics and the procurement cheat sheet — what to expect to pay by country × dosage
KEY TAKEAWAYExtreme prices are real: the highest are specialty/sterile formulations; the lowest are bulk API. The cheat sheet matrix is the take-home reference for procurement teams.
§7.2 Outlier forensics — top 10 highest and 10 lowest unit prices
↑ TOP 10 HIGHEST USD/UNIT
Date
Exporter
Country
Dosage
Qty
USD
$/unit
Why
Dec 2025
SUN PHARMACEUTIC…
Belgium
Injection
5K
$111K
$21.02
Sterile formulation premium
Nov 2025
SUN PHARMACEUTIC…
Belgium
Injection
6K
$116K
$19.70
Sterile formulation premium
Dec 2025
SUN PHARMACEUTIC…
Belgium
Injection
3K
$58K
$17.40
Sterile formulation premium
Nov 2025
SUN PHARMACEUTIC…
Belgium
Injection
2K
$31K
$16.46
Sterile formulation premium
Dec 2025
JPC GLOBAL
Singapore
Injection
20
$204.10
$10.21
Sterile formulation premium
Nov 2025
MILTON LIFECARE …
Bahrain
Injection
400
$2K
$5.99
Sterile formulation premium
Nov 2025
SUN PHARMACEUTIC…
Kenya
Vial
3K
$14K
$4.54
Specialty / small-batch
Nov 2025
VENUS REMEDIES LTD
Jamaica
Injection
4K
$14K
$3.60
Sterile formulation premium
Nov 2025
CHETAN & DIPTI (…
Uganda
Injection
5K
$18K
$3.56
Sterile formulation premium
Nov 2025
VENUS REMEDIES LTD
Saudi Arabia
Powder
11K
$36K
$3.43
Specialty / small-batch
↓ TOP 10 LOWEST USD/UNIT
Date
Exporter
Country
Dosage
Qty
USD
$/unit
Why
Nov 2025
SUN PHARMACEUTIC…
Brazil
Suspension
338
$2.67
$0.0079
Small sample / trial shipment
Dec 2025
VENUS REMEDIES LTD
Mexico
Solution
217K
$4K
$0.018
Dec 2025
VENUS REMEDIES LTD
Mexico
Injection
13K
$242.24
$0.018
Sterile formulation premium
Dec 2025
MDS ENTERPRISES
Ghana
Injection
500
$9.81
$0.020
Sterile formulation premium
Dec 2025
MDS ENTERPRISES
United Arab Emirates
Injection
500
$12.81
$0.026
Sterile formulation premium
Dec 2025
VENUS REMEDIES LTD
South Africa
Powder
20K
$665.41
$0.033
Nov 2025
VENUS REMEDIES LTD
Morocco
—
3
$0.114
$0.038
Small sample / trial shipment
Nov 2025
VENUS REMEDIES LTD
Morocco
Injection
20
$2.28
$0.114
Sterile formulation premium
Nov 2025
VENUS REMEDIES LTD
Morocco
—
20
$2.29
$0.115
Small sample / trial shipment
Nov 2025
ALKEM LABORATORI…
Nepal
Injection
31K
$6K
$0.191
Sterile formulation premium
§7.3 Procurement cheat sheet — median USD/unit by country × dosage
Fig 7.2 Median unit price by country × dosage form — darker cells = higher prices.
How to read: Each cell shows the median price per unit for that country-dosage combination. Dark blue = expensive, light = cheap. Blank cells = no shipments in that combination.
NEGOTIATION RANGE
Use each cell value as the anchor price. Typical dynamics:
Dosage form is the #1 price driver, not destination
Light cells = easy-entry markets for small suppliers
Dark cells = premium markets requiring regulatory investment
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Which Indian ports ship imipenem, which global ports receive it, and which corridors are high-value vs bulk
KEY TAKEAWAYImipenem leaves India through 11+ ports. The top 5 (DADRI ICD, DELHI AIR, MUMBAI AIR (SAHAR)) handle 82.3% of total USD. ICD moves 20% of shipments.
S FOR SUPPLIERS
Use the dumbbell to classify your port as high-value hub or bulk workhorse. Note the short-sea routes — Bangladesh, Sri Lanka, Myanmar and East Africa are the easiest logistics corridors for first-time exporters.
B FOR BUYERS
Use the destination port ranking to find which Indian ports serve your market. The lead-time estimates tell you what transit time to expect.
Fig 8.1 DADRI ICD handles $359K — top 11 Indian origin ports by trade value.
How to read: Each bar = one destination port worldwide. Bar length = USD value received from India.
§8.1 Reference transit times for key India → global corridors
Route
Mode
Transit time
Notes
NHAVA SHEVA SEA (JNPT) → US East Coast
Sea
22–28 days
Via Suez; 2–3 transshipments typical
NHAVA SHEVA SEA (JNPT) → Lagos (Nigeria)
Sea
18–24 days
Direct liner service available
MUMBAI AIR (SAHAR) → New York JFK
Air
3–5 days
Direct cargo; cold-chain available
MUNDRA SEA → Rotterdam
Sea
20–26 days
Via Suez; Hamburg also served
HYDERABAD AIR → London Heathrow
Air
2–4 days
Pharma-grade cargo corridor
CHENNAI SEA → Chittagong (Bangladesh)
Sea
7–12 days
Short-sea route; high frequency
RAXAUL → Birgunj (Nepal)
Road
1–2 days
Land border crossing
NHAVA SHEVA SEA (JNPT) → Mombasa (Kenya)
Sea
14–20 days
Direct or via Colombo hub
Table 8.1 — Reference times based on standard shipping corridors. Air = 2–5 days; sea = 7–28 days; road = 1–2 days. Add 3–7 days for customs clearance at destination.
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Trade corridors — origin port to mode of transport to destination region
KEY TAKEAWAYICD dominates at 20% of shipments. The alluvial traces every dollar from Indian origin port through transport mode to destination region.
ICD
$694K
47.0% of USD · 20.0% of ships
AIR
$663K
45.0% of USD · 62.2% of ships
SEA
$68K
4.6% of USD · 11.1% of ships
ROAD
$51K
3.4% of USD · 6.7% of ships
Fig 8.3 The dominant corridor is DADRI ICD → Sea → N. America ($359K).
How to read: Left = Indian origin ports. Middle = transport mode. Right = destination region. Ribbon thickness = USD value; color = mode. Follow the thickest ribbons to find the highest-value corridors.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market concentration, supply-chain risk, and the dependency patterns that signal where to act
KEY TAKEAWAYBelgium is the most concentrated destination (HHI 10000, 1 suppliers). Afghanistan is the most competitive (HHI 5075).
S FOR SUPPLIERS
The HHI barbell shows where competitors have locked up a market (concentrated = poaching opportunity) vs where you must compete on quality (fragmented). The slope chart reveals who is gaining ground.
B FOR BUYERS
The HHI barbell tells you whether your country has enough supplier options. If concentrated (red zone), you have fewer alternatives.
Fig 9.1 Belgium (HHI 10,000) is the most concentrated — Afghanistan (HHI 5,075) is the most competitive.
What is HHI? The Herfindahl-Hirschman Index measures how concentrated a market is among its suppliers. It ranges from 0 to 10,000. Below 1,500 (green zone) = many suppliers compete openly — healthy, competitive market with low risk. 1,500–2,500 (yellow zone) = a few suppliers hold significant share — moderate concentration. Above 2,500 (red zone) = one or two suppliers dominate the market — high risk for buyers who may lose supply, and hard to break into for new suppliers. Conclusion: 20 of 20 destination markets are concentrated (red zone). 0 are competitive (green zone). Buyers in red-zone markets should urgently qualify a second Indian supplier to reduce dependency risk.
§9.1 Single-source dependencies
Buyer
Country
Sole supplier
USD
Ships
Risk
L J S A D E C V
Mexico
VENUS REMEDIES LTD
$359K
1
HIGH
YUSEN LOGISTICS BENE…
Belgium
SUN PHARMACEUTIC…
$219K
3
HIGH
I+SOLUTIONS
Netherlands
SUN PHARMACEUTIC…
$203K
2
HIGH
S T C
Saudi Arabia
VENUS REMEDIES LTD
$150K
3
HIGH
LOBA IMPORT EXPORT SRL
Bolivia
KWALITY PHARMACE…
$65K
1
MEDIUM
L J S D C
Mexico
VENUS REMEDIES LTD
$54K
3
MEDIUM
PARTH PHARMA DISTRIB…
Nepal
ALKEM LABORATORI…
$35K
2
MEDIUM
LA COOPERATION PHARM…
Madagascar
G S PHARMA PVT LTD
$35K
1
MEDIUM
Conclusion: 24 buyers depend on exactly one Indian supplier, representing $1.3M in trade. For suppliers: each row is a competitor’s locked-in customer you can target.
§9.2 Multi-source resilience
Buyer
Country
Suppliers
USD
Dominant
Resilience
Conclusion: 0 of these buyers have HIGH resilience (3+ active suppliers). These are the hardest accounts to win but safest partners for long-term contracts.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market entry playbook and risk landscape by destination country
KEY TAKEAWAY15 target markets with specific entry approaches. Large suppliers: focus on regulated Tier 1 markets. Small/mid-size: start with Tier 2–3 (low barrier, growing demand).
§9.3 Sourcing recommendations · Table 9.1
Country
Tier
Lead
Price
Risk
Entry approach
Mexico
Tier 3 (emerging)
3–5 days (air)
$0.10–$1/unit
LOW
First-mover advantage
Belgium
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Netherlands
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Saudi Arabia
Tier 3 (emerging)
14–28 days (sea)
$1–$10/unit
LOW
First-mover advantage
Bolivia
Tier 3 (emerging)
14–28 days (sea)
$1–$10/unit
LOW
First-mover advantage
Nepal
Tier 3 (emerging)
14–28 days (sea)
$0.10–$1/unit
LOW
First-mover advantage
Madagascar
Tier 3 (emerging)
14–28 days (sea)
$1–$10/unit
LOW
First-mover advantage
Hong Kong
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Albania
Tier 3 (emerging)
14–28 days (sea)
$1–$10/unit
LOW
First-mover advantage
Hungary
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Afghanistan
Tier 3 (emerging)
14–28 days (sea)
$1–$10/unit
LOW
First-mover advantage
South Africa
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Uganda
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Jamaica
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Kenya
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
For suppliers: Tier 1 markets (US, UK, France) require regulatory investment but offer premium pricing. Tier 3 markets (emerging) have low barriers — ideal for first-time exporters. For buyers: Use the price band and lead time to benchmark your current supplier’s terms.
Fig 9.2 0 markets in the Growth Opportunity zone (competitive + growing). 15 in Fragile Dependency (concentrated + shrinking).
How to read: Each bubble = one destination. X-axis = HHI (concentration). Y-axis = growth %. Bubble size = USD. Green zone (top-left) = Growth Opportunity — competitive markets that are growing, best for new entrants. Red zone (bottom-right) = Fragile Dependency — concentrated + shrinking, high supply-chain risk. Conclusion: Key markets are the top growth opportunities.
09
PART V — ACTION
Action Plan & Easy-Entry Markets
12 prioritised actions + 15 low-competition destination countries for small & mid-size suppliers
KEY TAKEAWAYQuick Wins: execute this quarter. Big Bets: plan for next 6–12 months. Plus 15 countries with ≤5 Indian suppliers — the best entry points for SMEs.
S
FOR SUPPLIERS
ID
Action
Timing
Impact
A1
Pitch top single-source buyer in Mexico
This Q
HIGH
A2
Offer alternative to top multi-source buyer
This Q
HIGH
A3
Audit Belgium lock-ins (HHI 10000)
This Q
MED
A5
Enter Mexico (1 suppliers)
This Q
HIGH
A6
Enter Belgium (1 suppliers)
This Q
MED
A8
Build Belgium distribution
6–12m
HIGH
A9
Bundle injection/infusion catalog for premium markets
6–12m
MED
B
FOR BUYERS
ID
Action
Timing
Impact
A4
Monitor rising exporters (climbers)
This Q
MED
A7
Register for Mexico tenders
6–12m
HIGH
A10
Track quarterly HHI shifts across key destinations
This Q
LOW
A11
Map competitor buyer portfolios quarterly
This Q
MED
A12
Qualify second source for single-source buyers
This Q
MED
§9.4 Easy-entry markets — 15 countries with ≤5 Indian suppliers
#
Country
Region
Suppliers
Q4 USD
Growth
Barrier
Why this is easy
1
Mexico
Other
1
$414K
-98.8%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
2
Belgium
Other
1
$365K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
3
Netherlands
Other
1
$203K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
4
Saudi Arabia
Other
1
$150K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
5
Bolivia
Other
1
$65K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
6
Nepal
Asia
2
$51K
-100%
LOW
Only 2 Indian suppliers — near-monopoly, easy second-source entry
7
Madagascar
Africa
1
$35K
-100%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
8
Hong Kong
Asia
1
$28K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
9
Albania
Other
1
$28K
-100%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
10
Hungary
Other
1
$24K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
11
Afghanistan
Asia
2
$20K
0%
LOW
Only 2 Indian suppliers — near-monopoly, easy second-source entry
12
South Africa
Africa
2
$19K
0%
LOW
Only 2 Indian suppliers — near-monopoly, easy second-source entry
13
Uganda
Africa
1
$18K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
14
Jamaica
Other
1
$14K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
15
Kenya
Africa
2
$14K
0%
LOW
Only 2 Indian suppliers — near-monopoly, easy second-source entry
This report covers 45 2025-Q4 Imipenem shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/imipenem
10
PART VI — EVIDENCE REGISTER
Comprehensive Shipment Records by Region
Authoritative source behind all analytics in this report — every shipment appears exactly once
KEY TAKEAWAYThis section contains every one of the 45 2025-Q4 imipenem shipments, organised by Region → Exporter → Shipment rows. No row is duplicated.
S FOR SUPPLIERS
Jump to any destination country to see exactly who your competitors ship to, what they charge, through which port, and how often.
B FOR BUYERS
Jump to your country to see every Indian imipenem shipment that arrived in 2025-Q4: supplier, price, dosage, port.
§10.1 Global totals
SHIPMENTS
45
across all regions
TOTAL USD
$1.48M
2025-Q4 FOB value
UNITS
905.2K
tablets, capsules, etc.
SUPPLIERS
19
Indian exporters
BUYERS
26
global importers
COUNTRIES
26
destinations
§10.2 Regional breakdown
Africa
$88K
6.0%
7 ctry · 12 ships
Asia
$253K
17.2%
9 ctry · 15 ships
Europe
$629K
42.6%
5 ctry · 10 ships
Americas
$505K
34.2%
5 ctry · 8 ships
§10.3 Key insights from the data
🌍
Africa is the largest region at $88K (6.0%), spanning 7 countries.
🏢
19 Indian suppliers shipped to 26 buyers across 26 countries — average shipment value $33K.
📄
Top 0 markets: .
🔍
Every row below is real customs data — date, importer, dosage, brand, quantity, unit price, total USD, origin port, destination port, and transport mode.
All 24 global imipenem importers — complete list ranked by USD
KEY TAKEAWAYThis directory lists every company that imported Indian imipenem in 2025-Q4.
S FOR SUPPLIERS
Search for potential customers by country and dosage form.
B FOR BUYERS
Find your company and see which Indian supplier serves you.
#
Buyer
Country
Ships
USD
Primary supplier
Dosage forms
1
L J S A D E C V
Mexico
1
$359K
VENUS REMEDIES LTD
Injection
2
YUSEN LOGISTICS BENELUX BELGIUM
Belgium
3
$219K
SUN PHARMACEUTICAL I…
Injection
3
I+SOLUTIONS
Netherlands
2
$203K
SUN PHARMACEUTICAL I…
Powder
4
S T C
Saudi Arabia
3
$150K
VENUS REMEDIES LTD
Powder
5
LOBA IMPORT EXPORT SRL
Bolivia
1
$65K
KWALITY PHARMACEUTIC…
Injection
6
L J S D C
Mexico
3
$54K
VENUS REMEDIES LTD
Injection, Solution
7
PARTH PHARMA DISTRIBUTORS PVT LTD
Nepal
2
$35K
ALKEM LABORATORIES LTD
Injection
8
LA COOPERATION PHARMACEUTIQUEMALGAC
Madagascar
1
$35K
G S PHARMA PVT LTD
Powder for Injection
9
C P L
Hong Kong
1
$28K
VENUS REMEDIES LTD
Powder
10
E P H K
Hungary
1
$24K
VENUS REMEDIES LTD
Oral Solution
11
KAMCARE PHARMA LTD
Uganda
2
$18K
CHETAN & DIPTI (C&D)…
Injection
12
RANBAXY PHARMACEUTICALS PTY LTD
South Africa
1
$18K
SUN PHARMACEUTICAL I…
Injection
13
S GENERIX PHARMA DISTRIBUTORS
Nepal
1
$16K
M. J. BIOPHARM PVT LTD
Injection
14
MEDICAL PRODUCTS LTD
Jamaica
1
$14K
VENUS REMEDIES LTD
Injection
15
KHALIQ ZAZAI PVT LTD
Afghanistan
1
$11K
INDUS PHARMA PVT LTD
Injection
16
ETEMED MOSLEH LTD
Afghanistan
1
$9K
RESCUERS LIFE SCIENC…
Injection
17
OFFICE PHARMACEUTIQUE NATIONALE
Gabon
1
$2K
MEDNEXT BIOTECH LTD
Injection
18
GULF PHARMACIES W.L.L
Bahrain
1
$2K
MILTON LIFECARE PVT …
Injection
19
U L G
South Africa
1
$665.41
VENUS REMEDIES LTD
Powder
20
TO THE IMPORTING DEPARTMENT
Singapore
1
$204.10
JPC GLOBAL
Injection
21
FOR THE ORDER OF
Kenya
1
$139.60
3S CORP
Injection
22
OCTELLE CO LTD
Myanmar
1
$9.98
PANGENE BIOTECH LTD
Vial
23
PHARMAPROM
Morocco
2
$4.57
VENUS REMEDIES LTD
Injection
24
RANBAXY FARMACEUTICA LTDA
Brazil
1
$2.67
SUN PHARMACEUTICAL I…
Suspension
This report covers 45 2025-Q4 Imipenem shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/imipenem
Talk to our trade analyst
Need a custom imipenem report or a deeper dive into any market? Our team is ready.